- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04718324
PREMs on PROMs in Breast Disease (PREMs_PROMs) (PREMs_PROMs)
Electronic Patient Reported Outcome Measures (ePROMs) in Patients With Breast Disease: An Open-label, Randomized Controlled Trial on Patient Reported Experience Measures (PREMs) and Effectivity (PREMs_PROMs)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In recent years, large interest in the conduct and focus of clinical trials has focused to patient related outcomes and value-based healthcare. Patient Reported Outcome MeasureS, (PROMs) has become one of the standard instruments used for measuring outcomes; multiple PROMS have been extensively validated and are used in many clinical studies, but also in clinical routine. This is certainly the case for patients with breast disease, and in particular, breast cancer, where therapeutic advances in systemic and locoregional treatment have dramatically improved survival outcomes and shifted the interest in patient wellness, quality of life and health economy. However, their introduction and implementation require the development of certain logistics involving delivery to the patients, data procession and finally inclusion in patient journals and/or trial case report forms (CRFs).Additionally, Patient Reported Experience MeasureS (PREMS) allow for real-time feedback on the integration of care and can subsequently drive changes in health provision systems.
Currently, the paper-version of these PROMs, pPROMs, has been the standard version. With this comes some advantages, such as the ability to save and store filled PROMS, and for patients to fill them out when it suits them best, not having to answer all questions at once. At the same time, there are also disadvantages, such as that storing and processing the data is a tedious and resource-consuming task. Additionally, patients occasionally find it inconvenient to return the pPROMS by post; finally, the consumption of paper is not viewed as a environmentally friendly behaviour. At the same time and in the new era of digitalization, internet-based studies, such as surveys, become more popular. Most validated PROMS have been utilised in several occasions, and there is an effort for their standardisation in health care. These e-PROMs (electronic PROMs) seem to be more time-efficient since they do not have to be processed manually, but instead can be directly connected to digital systems which transform raw data (patient response) to big data and scores. It is also a more environment-friendly option since there is no need to print the questionnaires on paper or send them via mail to the patients and then back to the research centre. The question is how patients feel about these electronic versions and if their implementation may simplify PROMS, both for patients and healthcare givers and researchers alike. Even though the older generation at greater length is connected to the internet than before, and are more used to handling it, there are still those who are not comfortable with these new digital services.
Despite this being a reasonable hypothesis, no trials have examined this subject, that is to map the patients' attitudes toward participating in studies, nor which form is the preferred one, ePROMs or pPROMS. It would be reasonable to hypothesize that a more convenient mode of delivery would facilitate patients and would therefore increase response rates. Additionally, there is no randomized data on the optimal mode of PROMS delivery and process as far as monetary, personnel and structural resources are concerned
Reference population for the trial are women from the breast radiology unit, breast outpatient clinic and breast cancer patients from the oncology department of the participating sites. Patients will be asked to participate to this study through a letter sent they receive when receiving their appointment to the respective clinic/department. All patients are asked, regardless of diagnosis, sex or age; at this point, the researchers are not aware of individual information. If they consent, participants are randomised to either e-PROMs or pPROMs.
Trial hypothesis is that ePROMs are more convenient and time-efficient and that with these investigators can increase the response rate from 65% (which was observed in a pilot study previously conducted at the breast outpatient clinic at Uppsala University Hospital) to 80%.The trial is designed as a superiority trial to detect for a 0.15 difference between arms, with a 2-sided p-value=0.05 and 80% power. Sample size calculation was performed with (SampleSize4ClinicalTrials and TrialSize packages). This responds to 109 patients per arm. Patient allocation (1:1) is performed through permuted block randomisation performed on the R statistical software (randomizeR package) in blocks of 8.
Patients that provide oral and written consent for the trial are anonymised and receive a unique study number. They willingly provide contact details (address and e-mail address), in order to receive PROMS after randomization. Patients may decline mode of PROMS delivery, if they prefer otherwise. Patient preference is registered. In analyses, the "intention-to-treat" principle will be followed, but per protocol analyses is intended if the crossover is deemed significant (>10%).
Data process and analysis
Once filled out, the anonymised ePROMs will be automatically stored to the Uppsala University servers. They are extractable as a Microsoft Excel data sheet. pPROMS will be stored in paper form in a safe location at the participating site. All raw data from both arms will be transferred in an Excel database. This raw data will be processed through algorithms specific to each PROMS to allow for the calculation of the respective PROMS scores.
The time required for this procedure will be registered for statistical analyses.
Patient data to be utilised in the analysis is age and site of recruitment. Other data to be registered are monetary costs for pPROMS postal, monetary costs for pPROMS related consumable materials and hourly cost for the documentation and registration of PROMS in patient electronic journals.
Data and patient safety
Patient data will be treated according to the General Data Protection Regulation (GDPR). The trial is not expected to affect treatment of patients or affect diagnostic work-up or treatment modality. Participants will not receive monetary compensation. For participants that are wishing it, PROMS scores will be included in their journals.
Publication
Trial results are expected to be submitted for publication in peer-reviewed journals. Positive and negative results as well as subgroup analyses for primary characteristics such as patient age are expected to be reported.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Uppsala, Sweden, 75185
- Uppsala University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients seeking or being treated for perceived or verified, benign or malignant breast disease.
- Women undergoing screening mammography.
Exclusion Criteria:
- Linguistic barriers.
- Deprivation of liberty.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: e-PROMS
Patients allocated to the e-PROMS arm will fill an online version of PROMS and then respond to the e-PREMS questionnaire.
|
Participants randomised to the e-PROMS arm will receive a safe link to the e-PROMS and a unique identification number in the electronic form, so as to preserve anonymity.
This is a one-time intervention
|
Active Comparator: p-PROMS
Patients allocated to the p-PROMS arm will fill in PROMS in paper form (p-PROMS) and then respond to the p-PREMS questionnaire.
|
Participants randomised to the p-PROMS arm will receive the PROMS and PREMS questionnaires and a unique identification number in paper form.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate
Time Frame: Up to 8 weeks after receiving the questionnaires
|
Number of participants who answered the questionnaires divided by number of participants who were allocated to the respective arm.
Analyses will be performed without and with "reminders", per intention-to-treat and per protocol.
|
Up to 8 weeks after receiving the questionnaires
|
Patient Reported Experience outcomes (PREMS)
Time Frame: Up to 8 weeks after receiving the questionnaires
|
PREMS score per respective arm.
The PREMS score will be standard Likert items ranging from 1 to 7 and 1 to 5, with higher scores meaning a better outcome.
Analyses will be performed without and with "reminders", per intention-to-treat and per protocol.
|
Up to 8 weeks after receiving the questionnaires
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of response
Time Frame: Up to 8 weeks after receiving the questionnaires
|
Average time of response per arm.
Analyses will be performed without and with "reminders", per intention-to-treat and per protocol.
|
Up to 8 weeks after receiving the questionnaires
|
Procedure-related costs
Time Frame: Up to 8 weeks after receiving the questionnaires
|
Monetary costs per arm, including direct monetary costs and working hours for researchers and healthcare professionals to obtain PROMS.
Analyses will be performed without and with "reminders", per intention-to-treat and per protocol.
|
Up to 8 weeks after receiving the questionnaires
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Andreas Karakatsanis, PhD, Uppsala University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UUBreast02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on e-PROMS
-
University of Texas at AustinRecruiting
-
Universitätsklinikum Hamburg-EppendorfCompleted
-
Universitaire Ziekenhuizen KU LeuvenSemmelweis UniversityActive, not recruitingEndometriosis | Endometriosis-related Pain | Endometriosis, Rectum | Endometriosis; BowelBelgium, Hungary
-
Centro Hospitalar De São João, E.P.E.CompletedDegenerative Diseases, Spinal CordPortugal
-
University of AlbertaAlberta Health servicesActive, not recruitingChronic Kidney Disease Requiring Chronic DialysisCanada
-
Helsinki University Central HospitalActive, not recruitingProstate CancerFinland
-
Istituto Ortopedico RizzoliRecruiting
-
José Manuel Afonso MoreiraTerminatedQuality of Life | Cardiac Rehabilitation | Rehabilitation Exercise | Patient-Reported Outcome MeasuresPortugal
-
The Christie NHS Foundation TrustCompletedCancerUnited Kingdom
-
Istituto Ortopedico RizzoliRecruitingKnee Discomfort | Approach-Approach ConflictItaly